一项关于二甲双胍作为伴随疗法用于接受雄激素剥夺治疗的前列腺癌患者的开放标签试点研究。
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
作者信息
Zhu Wenhui, Xu Hua, Ma Jing, Guo Jianming, Xue Wei, Gu Baojun, Sheng Lu, Yao Xudong, Sun Fukang, Gong Jian, Qiu Weiliang, Ding Qiang, Jiang Haowen
机构信息
Department and Institute of Urology, Huashan Hospital, Shanghai, China.
出版信息
Urol Int. 2017;98(1):79-84. doi: 10.1159/000448691. Epub 2016 Sep 30.
PURPOSE
The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation therapy (ADT).
METHODS
Between March 2013 and June 2014, 62 newly diagnosed patients of prostate cancer (PCa) due to receive ADT were recruited from 7 hospitals in Shanghai. Patients were randomized to respectively receive ADT (n = 31) and ADT + metformin (n = 31) for 6 months. Fasting and postprandial serum levels of insulin and C-peptide, blood glucose, prostate specific antigen, body mass index (BMI) and waist circumference (WC) were measured at the beginning and end of 6-month treatment.
RESULTS
Baseline characteristics were comparable between the 2 groups. Controlling for baseline levels, the ADT group had significantly higher levels of fasting glucose (p = 0.01) and higher WC (p = 0.04) than the ADT + metformin group. The levels of insulin, C-peptide and BMI did not differ significantly.
CONCLUSIONS
Metformin may be potentially efficient as a concomitant therapy on patients with PCa undergoing androgen deprivation treatment.
目的
本研究旨在评估二甲双胍对接受雄激素剥夺治疗（ADT）的中国男性患者胰岛素、C肽和体重的影响。
方法
2013年3月至2014年6月期间，从上海7家医院招募了62例因接受ADT而新诊断的前列腺癌（PCa）患者。患者被随机分为两组，分别接受ADT（n = 31）和ADT + 二甲双胍（n = 31）治疗6个月。在6个月治疗开始和结束时，测量空腹和餐后血清胰岛素、C肽、血糖、前列腺特异性抗原、体重指数（BMI）和腰围（WC）水平。
结果
两组的基线特征具有可比性。在控制基线水平后，ADT组的空腹血糖水平显著高于ADT + 二甲双胍组（p = 0.01），WC也更高（p = 0.04）。胰岛素、C肽和BMI水平无显著差异。
结论
二甲双胍作为接受雄激素剥夺治疗的PCa患者的辅助治疗可能具有潜在疗效。
Zotero 插件